Autolus Therapeutics to present data at ASH Meeting

Autolus Therapeutics (AUTL) announces the online publication of five abstracts submitted to the American Society of Hematology, ASH, Annual Meeting, to be held December 6-9, 2025, in Orlando, Florida. “Data to be presented at the upcoming ASH Annual Meeting continue to underscore the potential for obe-cel to produce long-term outcomes in severe and difficult to treat patient populations in both hematological oncology and autoimmune indications,” said Dr. Christian Itin, Autolus Chief Executive Officer. “In addition to Autolus’ presentations, we look forward to the presentation of data from real-world experience of the ROCCA consortium evaluating CAR T therapy for relapsed/refractory adult ALL patients. We are encouraged with the real-world experience with obe-cel and believe it will support momentum for product uptake.”